Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Isotechnika Pharma Inc IPHAF



GREY:IPHAF - Post by User

Comment by BornReady1970on Jun 25, 2010 4:47pm
394 Views
Post# 17223221

RE: Data driven

RE: Data drivenThere are two types of data:

Clinical - ISA has good clinical data. I don't think there is anyone on this board that has ever effectively shot holes in Volco, and most are very positive on the drug.

Business - ISA has taken a very promising drug and managed to move it's share price from over $5.00 to
.25. That is real data. ISA has publicaly disclosed that it has cash flow until Q4 of 2010. That is real data.

Any ISA investor has to answer one very simple question...

Will good clinical data overcome poor business data? If you think so then BUY; if not then SELL.

If you want to hedge, the only hedge available is to buy Paladin. With Paladin you get both good clinical data and good busniess data.

I still think the share price will settle out under
.20 before we get any more news.
<< Previous
Bullboard Posts
Next >>